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simvastatin/atorvastatin strategy was estimated at £74.4 m with
62.9% reaching the TC target of <4.0 mmol/L. Treatment with
the simvastatin/rosuvastatin strategy was estimated to cost 
£70.3 m with 66.5% of patients reaching this target. CON-
CLUSIONS: A simvastatin/rosuvastatin strategy is more cost-
effective than a simvastatin/atorvastatin strategy at treating
newly eligible Scottish patients, with cost savings of £4.1 m and
an additional 3.6% of patients (13,314) reaching the TC target
of <4.0 mmol/L.
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OBJECTIVE: To determine the impact of ventricular arrhyth-
mias on hospitalization costs for acute myocardial infarction
(AMI) patients. METHODS: A retrospective cohort study design
was used. Adult patients with primary diagnosis of AMI (ICD-
9 code: 410.x1), between July 2003 and June 2004, were iden-
tiﬁed from a large retrospective database of approximately ﬁve
hundred hospitals in the United States. The AMI patients were
classiﬁed based on secondary diagnosis of ventricular arrhyth-
mia into three groups: AMI with sustained ventricular tachycar-
dia (sustained VT)/ventricular ﬁbrillation (VF) (ICD-9 code:
427.4x, 427.5); AMI with paroxysmal ventricular tachycardia
(PVT) (ICD-9 code 427.1); and AMI without ventricular
arrhythmia. Multivariate hierarchical regression analysis was
performed to study the impact of ventricular arrhythmias on hos-
pitalization costs controlling for patient demographics, hospital
characteristics, site of infarction, history of coronary heart
disease, co-morbidities and procedures such as percutaneous
coronary intervention (PCI), bypass grafts and catheterization.
RESULTS: A total of 91,225 patients with primary diagnosis of
AMI were identiﬁed, of which 8125 (8.9%) patients had a sec-
ondary diagnosis of ventricular arrhythmia, including sustained
VT/VF (N = 3004; 3.3%) and PVT (N = 5121; 5.6%). A major-
ity of the AMI patients with ventricular arrhythmia were male
(70.2%), Caucasian (73.4%) and ≥65 years (55%). Average
unadjusted hospitalization costs were signiﬁcantly higher (p <
0.001) in AMI patients with sustained VT/VF ($26,524 ±
29,869) and PVT ($23,447 ± 27,704) than those for AMI
patients without ventricular arrhythmia ($14,449 ± 16,638).
Sustained VT/VF (b = $9220, p < 0.001) and PVT (b = $8125,
p < 0.001) were found to signiﬁcantly increase hospital costs in
AMI patients in the regression model. Presence of diabetes (p <
0.001), cancer (p < 0.001), procedures like PCI, bypass grafts
and catheterization (p < 0.001) were the other signiﬁcant posi-
tive predictors of hospital costs. CONCLUSIONS: Ventricular
arrhythmias in AMI patients were associated with signiﬁcantly
higher hospitalization costs. Prevention of ventricular arrhyth-
mia in AMI patients could potentially yield beneﬁts in terms of
reduced hospitalization costs.
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OBJECTIVES: Nesiritide is a new technology to be introduced
to the Brazilian health care system for the treatment of acute
decompensated heart failure (ADHF). This study evaluated the
cost impact of nesiritide versus standard care (SC) for the private
hospital sector. METHODS: As no clinical or usage data were
available for Brazil, we started from a published US study (Lenz,
2004) that detailed resource use of nesiritide versus SC in the
treatment of ADHF over a 3 months period. Key ﬁndings were
in line with other published resource use studies. Brazilian cost
data (2006) were then applied to the ﬁndings. In a sensitivity
analysis, key resource use items were adapted to the Brazilian
clinical setting based on expert opinion and literature. RESULTS:
The Lenz study demonstrated that nesiritide can impact posi-
tively on resource use: reduced length of stay in the ICU unit (1
day); reduced number of re-admissions (25.9% vs 34.2% SC);
reduced need for co-medication. Applying Brazilian hospital cost
data, rendered treatment with nesiritide cost-saving versus SC.
For type A hospitals, treatment with nesiritide costed R$10,486
versus R$11,403 with SC, a saving of R$917 (401US$) per
patient. For type C hospitals, the costs were respectively R$7782
(nesiritide) and R$8016 (SC), a saving of R$234 (US$102) per
patient. In a sensitivity analysis, the longer average length of stay
in Brazilian hospitals was reﬂected and resulted in larger poten-
tial savings. CONCLUSIONS: The cost-savings found in this
study are more modest than the ones reported for US settings,
reﬂecting the reality of lower health care costs in Brazil.
However, introducing nesiritide to the Brazilian private hospital
setting has the potential of reducing hospital-related costs for
treating ADHF. A local observational study would be needed to
conﬁrm these results. R$: reais (Brazilian currency), exchange
rate 30-05-2006.
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OBJECTIVES: To measure the comorbiditiy burden, the eco-
nomic impact and some therapeutic goals, among patients with
cardiovascular disease (CVD) in several primary care centres
(PCC) in daily medical practice. METHODS: A retrospective
study was performed based on data from patients with diag-
nosis of CVD (CIAP codiﬁcation), aged >35 years, from 
ﬁve Spanish PCC. Main analysed variables were: age, sex,
events/comorbidities, sanitary resources consumption, clinical
parameters (diastolic blood pressure [DBP], systolic blood pres-
sure, total cholesterol, LDLc, HDLc, HBA1c, basal glycemia,
triglycerides, body max index [BMI]). A cost model for each
patient was developed by differentiating semiﬁxed cost (per-
sonal, external personal and purchases) from the variables (phar-
macy, laboratory, derivations, etc.). Costs were adjusted using an
ANCOVA multivariant analysis, based on estimated marginal
means (Bonferroni correction). RESULTS: Of the 51,515
patients included in the analysis, 2600 (5.0%) had a history 
of CVD (CI: 4.2–5.8%); 68.2% were men. Mean number of
events/patients/year was 8.1 ± 4.2 vs. 5.2 ± 3.6 (p = 0.000) and
number of visits/patient/year was 15.1 ± 13.5 vs. 8.4 ± 8.2 (p =
0.000). The main associated variables were: males (OR = 3.4;
CI: 3.1–3.8; p = 0.000), dyslipidemia (OR = 2.0; CI: 1.8–2.2; 
p = 0.000) and diabetes mellitus (OR = 1.9; CI: 1.6–2.1; p =
0.000). €41.5 million in costs were quantiﬁed (pharmacy:
69.3%, semiﬁxed: 21.7%). The unitary costs per comorbidity-
adjusted life-year per patient (marginal means) was €1484.87
